These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 22508310)

  • 21. Treatment of experimental cryptococcal meningitis and disseminated candidiasis with SCH39304.
    Perfect JR; Wright KA; Hobbs MM; Durack DT
    Antimicrob Agents Chemother; 1989 Oct; 33(10):1735-40. PubMed ID: 2556078
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Natural compounds from freshwater mussels disrupt fungal virulence determinants and influence fluconazole susceptibility in the presence of macrophages in
    Gutierrez-Gongora D; Woods M; Prosser RS; Geddes-McAlister J
    Microbiol Spectr; 2024 Mar; 12(3):e0284123. PubMed ID: 38329361
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of the anticryptococcal activity of the antibiotic polymyxin B in vitro and in vivo.
    Zhai B; Lin X
    Int J Antimicrob Agents; 2013 Mar; 41(3):250-4. PubMed ID: 23313397
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A defect in iron uptake enhances the susceptibility of Cryptococcus neoformans to azole antifungal drugs.
    Kim J; Cho YJ; Do E; Choi J; Hu G; Cadieux B; Chun J; Lee Y; Kronstad JW; Jung WH
    Fungal Genet Biol; 2012 Nov; 49(11):955-66. PubMed ID: 22975303
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification and properties of plasma membrane azole efflux pumps from the pathogenic fungi Cryptococcus gattii and Cryptococcus neoformans.
    Basso LR; Gast CE; Bruzual I; Wong B
    J Antimicrob Chemother; 2015 May; 70(5):1396-407. PubMed ID: 25630649
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A repurposing approach identifies off-patent drugs with fungicidal cryptococcal activity, a common structural chemotype, and pharmacological properties relevant to the treatment of cryptococcosis.
    Butts A; DiDone L; Koselny K; Baxter BK; Chabrier-Rosello Y; Wellington M; Krysan DJ
    Eukaryot Cell; 2013 Feb; 12(2):278-87. PubMed ID: 23243064
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interactions between triazoles and amphotericin B against Cryptococcus neoformans.
    Barchiesi F; Schimizzi AM; Caselli F; Novelli A; Fallani S; Giannini D; Arzeni D; Di Cesare S; Di Francesco LF; Fortuna M; Giacometti A; Carle F; Mazzei T; Scalise G
    Antimicrob Agents Chemother; 2000 Sep; 44(9):2435-41. PubMed ID: 10952592
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In-vitro activity of dicationic aromatic compounds and fluconazole against Cryptococcus neoformans and Candida spp.
    Del Poeta M; Bixel AS; Barchiesi F; Tidwell RR; Boykin D; Scalise G; Perfect JR
    J Antimicrob Chemother; 1999 Aug; 44(2):223-8. PubMed ID: 10473229
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Estrogen receptor antagonists are anti-cryptococcal agents that directly bind EF hand proteins and synergize with fluconazole in vivo.
    Butts A; Koselny K; Chabrier-Roselló Y; Semighini CP; Brown JC; Wang X; Annadurai S; DiDone L; Tabroff J; Childers WE; Abou-Gharbia M; Wellington M; Cardenas ME; Madhani HD; Heitman J; Krysan DJ
    mBio; 2014 Feb; 5(1):e00765-13. PubMed ID: 24520056
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans.
    Perfect JR; Cox GM; Dodge RK; Schell WA
    Antimicrob Agents Chemother; 1996 Aug; 40(8):1910-3. PubMed ID: 8843302
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Berberine Antifungal Activity in Fluconazole-Resistant Pathogenic Yeasts: Action Mechanism Evaluated by Flow Cytometry and Biofilm Growth Inhibition in Candida spp.
    da Silva AR; de Andrade Neto JB; da Silva CR; Campos Rde S; Costa Silva RA; Freitas DD; do Nascimento FB; de Andrade LN; Sampaio LS; Grangeiro TB; Magalhães HI; Cavalcanti BC; de Moraes MO; Nobre Júnior HV
    Antimicrob Agents Chemother; 2016 Jun; 60(6):3551-7. PubMed ID: 27021328
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro antifungal activities of amphotericin B, 5-fluorocytosine, fluconazole and itraconazole against Cryptococcus neoformans isolated from cerebrospinal fluid and blood from patients in Serbia.
    Trpković A; Pekmezović M; Barać A; Crnčević Radović L; Arsić Arsenijević V
    J Mycol Med; 2012 Sep; 22(3):243-8. PubMed ID: 23518082
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Decreasing fluconazole susceptibility of clinical South African Cryptococcus neoformans isolates over a decade.
    Naicker SD; Mpembe RS; Maphanga TG; Zulu TG; Desanto D; Wadula J; Mvelase N; Maluleka C; Reddy K; Dawood H; Maloba M; Govender NP;
    PLoS Negl Trop Dis; 2020 Mar; 14(3):e0008137. PubMed ID: 32231354
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Invasive fungal infection by Cryptococcus neoformans var. grubii with bone marrow and meningeal involvement in a HIV-infected patient: a case report.
    Vechi HT; Theodoro RC; de Oliveira AL; Gomes RMODS; Soares RDA; Freire MG; Bay MB
    BMC Infect Dis; 2019 Mar; 19(1):220. PubMed ID: 30832607
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Experimental Evolution of Antifungal Resistance in Cryptococcus neoformans.
    Bermas A; Geddes-McAlister J
    Curr Protoc Microbiol; 2020 Dec; 59(1):e116. PubMed ID: 32986290
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B against Cryptococcus neoformans.
    Klepser ME; Wolfe EJ; Pfaller MA
    J Antimicrob Chemother; 1998 Mar; 41(3):397-401. PubMed ID: 9578168
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro and in vivo antifungal activities of T-2307, a novel arylamidine, against Cryptococcus gattii: an emerging fungal pathogen.
    Nishikawa H; Fukuda Y; Mitsuyama J; Tashiro M; Tanaka A; Takazono T; Saijo T; Yamamoto K; Nakamura S; Imamura Y; Miyazaki T; Kakeya H; Yamamoto Y; Yanagihara K; Mukae H; Kohno S; Izumikawa K
    J Antimicrob Chemother; 2017 Jun; 72(6):1709-1713. PubMed ID: 28201509
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular identification, antifungal resistance and virulence of Cryptococcus neoformans and Cryptococcus deneoformans isolated in Seville, Spain.
    Gago S; Serrano C; Alastruey-Izquierdo A; Cuesta I; Martín-Mazuelos E; Aller AI; Gómez-López A; Mellado E
    Mycoses; 2017 Jan; 60(1):40-50. PubMed ID: 27633849
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro synergistic effects of chlorpromazine and sertraline in combination with amphotericin B against Cryptococcus neoformans var. grubii.
    Rossato L; Loreto ÉS; Zanette RA; Chassot F; Santurio JM; Alves SH
    Folia Microbiol (Praha); 2016 Sep; 61(5):399-403. PubMed ID: 26847460
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro susceptibility of the yeast pathogen cryptococcus to fluconazole and other azoles varies with molecular genotype.
    Chong HS; Dagg R; Malik R; Chen S; Carter D
    J Clin Microbiol; 2010 Nov; 48(11):4115-20. PubMed ID: 20844209
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.